

# Circulating tumour-derived DNA in metastatic soft tissue

Oncotarget

9, 10549-10560

DOI: [10.18632/oncotarget.24278](https://doi.org/10.18632/oncotarget.24278)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. <i>Cancer Letters</i> , 2018, 439, 66-77.	3.2	32
2	Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3825.	1.8	21
3	Different methylation levels in the KLF4, ATF3 and DLEC1 genes in the myometrium and in corpus uteri mesenchymal tumours as assessed by MS-HRM. <i>Pathology Research and Practice</i> , 2019, 215, 152465.	1.0	5
4	Detection of circulating sarcoma tumor cells using a microfluidic chip-type cell sorter. <i>Scientific Reports</i> , 2019, 9, 20047.	1.6	10
5	Prospective Evaluation of the Concordance of Commercial Circulating Tumor DNA Alterations with Tumor-Based Sequencing across Multiple Soft Tissue Sarcoma Subtypes. <i>Cancers</i> , 2019, 11, 1829.	1.7	9
6	Cell-free DNA in blood as a noninvasive insight into the sarcoma genome. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100827.	2.7	8
7	Sarcoma treatment in the era of molecular medicine. <i>EMBO Molecular Medicine</i> , 2020, 12, e11131.	3.3	154
8	The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids. <i>Journal of Cancer</i> , 2020, 11, 5293-5308.	1.2	12
9	The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4483.	1.8	8
10	Incidence and prognosis of distant metastasis in malignant peripheral nerve sheath tumors. <i>Acta Neurochirurgica</i> , 2021, 163, 521-529.	0.9	6
11	A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020, 10, 602153.	1.3	5
12	Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. <i>Cancers</i> , 2021, 13, 2189.	1.7	8
13	Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas. <i>Bone and Joint Research</i> , 2021, 10, 602-610.	1.3	2
14	Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?. <i>Biomedicines</i> , 2021, 9, 1315.	1.4	10
15	Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers. <i>Journal of Surgical Oncology</i> , 2022, 125, 239-245.	0.8	5
16	Liquid biopsy in bone sarcomas and identification of new biomarkers. , 2022, , 487-500.		0
17	Molecular profiling of soft-tissue sarcomas with FoundationOne <sup>®</sup> Heme identifies potential targets for sarcoma therapy: a single-centre experience. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110291.	1.4	3
18	Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?. <i>Current Oncology Reports</i> , 2020, 22, 12.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , 2020, 11, 188-211.	0.8	54
20	Mutational Testing in Gastrointestinal Stromal Tumor. <i>Current Cancer Drug Targets</i> , 2019, 19, 688-697.	0.8	6
21	Multidisciplinary treatment of soft tissue sarcomas: An update. <i>World Journal of Clinical Oncology</i> , 2020, 11, 180-189.	0.9	19
22	Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 732525.	1.3	2
24	Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
25	Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	3
27	Individual Radiation Sensitivity and Biomarkers: <i>Molecular Radiation Biology</i> . , 2023, , 387-424.		0